Literature DB >> 7567332

Chemotherapy plays a major role in the inhibition of catch-up growth during maintenance therapy for childhood acute lymphoblastic leukemia.

J J Groot-Loonen1, B J Otten, M A van t' Hof, R J Lippens, G B Stoelinga.   

Abstract

OBJECTIVE: In children treated for acute lymphoblastic leukemia (ALL), catch-up growth occurs after cessation of therapy and not during maintenance therapy. In this study we investigated whether this inhibition of catch-up growth during maintenance treatment is attributable to the influence of chemotherapy or to the influence of corticosteroids. PATIENTS: Forty-six children treated for ALL were included in the study. In 27 patients maintenance therapy comprised vincristine (VCR), prednisone (Pred), or dexamethasone (Dexa) alternated with 6-mercaptopurine (6-MP) and methotrexate (MTX) and 19 patients received maintenance therapy with 6-MP and MTX only. Treatment did not include cranial irradiation.
RESULTS: Statural growth during maintenance treatment was comparable in both groups over the study period of 1.5 years.
CONCLUSION: Chemotherapy with 6-MP and MTX, and not corticosteroids, is the main factor that prevents catch-up growth from occurring during maintenance therapy for ALL.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7567332

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  2 in total

Review 1.  Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group.

Authors:  A Matsuzaki; E Ishii; Y Nagatoshi; H Eguchi; H Koga; F Yanai; H Inada; K Nibu; Y Tamai; K Akiyoshi; H Nakayama; T Hara; H Take; S Miyazaki; J Okamura
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

2.  Paley's multiplier method does not accurately predict adult height in children with bone sarcoma.

Authors:  Magdalena Maria Gilg; Christine Wibmer; Dimosthenis Andreou; Alexander Avian; Petra Sovinz; Werner Maurer-Ertl; Per-Ulf Tunn; Andreas Leithner
Journal:  Clin Orthop Relat Res       Date:  2014-04-29       Impact factor: 4.176

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.